A Powerful New Direction in Hospital Strategic Planning

Like any business, hospitals need strategic plans to chart their future. Rarely do they go smoothly, but with flexibility and agility, organizations can carefully navigate them. Jerry Darby, VP, Strategic Advisory Services at Covalus, shared his experiences and predictions for the space on Plan. Build. Equip.

Darby has 30 years of healthcare planning consulting experience. He started his career as a pharmacist working in retail and hospital pharmacies. An early challenge of helping a hospital regain its controlled substance license made him realize he wanted to be on the business side of the industry.

“Supporting hospitals in unique situations is interesting. I’ve worked with great people, and, as a consultant, you come into opportunities created by others,” Darby said.

Over the years, Darby has helped prominent hospitals like the Mayo Clinic and Mass General with planning. He explained the plan is just the first step. “You can create the best plan in the world, but with no way to implement it, it’s less likely to be successful.”

The process can be arduous and requires massive changes. “There are hard conversations, but flexibility must be part of the thing, because many things change, and you have to be able to adjust,” Darby added.

The most dramatic change for healthcare has been the pandemic. Darby recalled that some strategic plans had foresight. He mentioned transitioning from double patient rooms to single patient rooms, hospitals being more ICU ready, and other operational pieces.

Now, technology is where investment needs to go, including telehealth, remote monitoring, and ways to evaluate patients from a distance. Darby spoke about the next transition hurdle—being consumer-centric. “Hospitals need to orient around the consumer, and I think the pandemic is changing this and views on healthcare.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More